An industry leader in
biopharmaceutical contract manufacturing
About MabPlex
MabPlex provides global CDMO services in the development and manufacturing of biopharmaceuticals, including mAbs, recombinant proteins, ADCs and bispecifics. We offer our partners contract services from DNA to finished drug product. Our technical expertise allows us to provide effective high quality solutions for our partners biomanufacturing needs. At both our US R&D site and our manufacturing site in Yantai, China, MabPlex delivers our commitment to our partners through our quality manufacturing, meeting their expectations.
- Comprehensive biologics development and manufacturing solutions for customers globally
- Multiple Single Use 2000L Bioreactors for GMP Manufacturing
- One of the few providers of large-scale ADC production worldwide
- Services for pre-clinical studies through commercial production
- Senior Management Team averaging over 20 years of industry experience globally
MISSION
CUSTOMER FOCUSED
Professional Integrity
Service Excellence
Our JOURNEY
MabPlex International, Ltd. was established.
Yantai headquarter moved to new location and production R&D center officially opened.
MabPlex USA, Inc. established.
Passed environmental management system and occupational health and safety management system certification.
Obtained Biotechnology Product "Pharmaceutical Production License".
Established San Diego R & D Center.
Established MabPlex Biomedical (Shanghai) Co., Ltd.
Passed the intellectual property management system certification.
GMP operation of MabPlex Phase II R &D and production center started.
Shandong province public service platform for antibody drug R&D and industrialization unveiled.
Completed first round of financing, with the financing amount of 390 million yuan.
MabPlex M2 GMP facility was put into commercial operation.
MabPlex was awarded “ADC CDMO Growth and Leadership Award" by Frost & Sullivan in USA.
MabPlex was selected as a national high-tech enterprise.
MabPlex completed the first B round of financing, with a financing amount of 510 million yuan.
MabPlex won the "Asia-Pacific Antibody and ADC Manufacturing Excellence Award".
MabPlex was selected as one of top enterprises in Shangdong Province.
MabPlex was selected as one of China's "Little Giant" enterprises.
MabPlex ranked as one of "Top 10 CROs" by Life Sciences Review 2021.
MabPlex was selected as one of "Top CMO in APAC 2022".
MabPlex International Biomedical Innovation Center and Operation Headquarters started construction.
MabPlex and SUMGEN reached a strategic cooperation for the commercial production of SG301 project.
MabPlex hosted "CDMO Efficiently Assist Drug Research and Development conference".
MabPlex was awarded as "Top CMO in China".
MabPlex was awarded as 2023 "Influential CDMO Company of the Year".
LOCATIONS
MabPlex is headquartered in Yantai Economic and Development Area, a city in the northeast of the Shandong Province. It is bordered by both the Yellow Sea and the Bohai Sea. YEDA, Yantai Economic and Development Area, is one of the first 14 state-level development zones approved by the State Council of China in 1984. Yantai has attracted investments from more than 40 countries and regions, and more than 80 Fortune 500 Companies.
The biopharmaceutical industry in Yantai has prospered in the last two years. The number of biopharmaceutical corporations has reached 100, in which 13 companies have gone public in domestic and abroad market. In 2018, the total income of Yantai biopharmaceutical was 11 billion U.S dollars, with a year-on-year growth of 13.3%.
Yantai is also a tourist attraction.